Clinical Trial Update: Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating thalidomide for secondary prophylaxis of gastrointestinal bleeding in cirrhotic patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Gastrointestinal Hemorrhage
• Portal Hypertension

Drugs mentioned

• Thalomid (thalidomide)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Gastrointestinal Hemorrhage, Portal Hypertension | Phase 3 | Status: WITHDRAWN